Virtual Reality Therapy for Mal de Débarquement Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial uses VR goggles to help patients with Mal de Débarquement Syndrome (MdDS) improve their balance and reduce dizziness. The treatment includes additional exercises to help patients get used to movement and reduce their sensitivity to visual motion. The goal is to provide a more accessible and effective treatment option for MdDS patients. The treatment involves specific head movements while watching visual patterns, leading to improvement in MdDS symptoms.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is virtual reality therapy safe for treating vestibular conditions?
How is the DevRobust Treatment for Mal de Débarquement Syndrome different from other treatments?
The DevRobust Treatment is unique because it uses virtual reality to replicate a specific therapy that involves passive head movements while watching moving stripes, which helps readjust the vestibulo-ocular reflex (VOR) and alleviate symptoms. This approach is novel compared to traditional vestibular rehabilitation, which may not specifically target the maladaptation seen in Mal de Débarquement Syndrome.12345
What data supports the effectiveness of the treatment Virtual Reality Therapy for Mal de Débarquement Syndrome?
A case report showed that using a virtual reality environment to replicate a treatment involving head movements and visual stimuli led to complete symptom resolution in a patient with Mal de Débarquement Syndrome after just two sessions. Additionally, virtual reality-assisted therapy has been shown to improve treatment outcomes for vestibular disorders compared to conventional therapy.12467
Who Is on the Research Team?
Sergei Yakushin
Principal Investigator
Ichan Scool of Medicine at Mount Sinai
Are You a Good Fit for This Trial?
This trial is for individuals with Mal de Débarquement Syndrome who feel better when in passive motion. It's not suitable for those with claustrophobia, certain neurological disorders like MS or epilepsy, abnormal inner ear function tests, injuries affecting mobility without support, prior VOR readaptation treatment, or high anxiety levels.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive VOR readaptation treatment with either full-field OKS or VR goggles for 1-2 hours a day over 5 days
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at baseline and 6 months
Extension
Participants may receive additional treatment focusing on VID or MS susceptibility if symptoms persist
What Are the Treatments Tested in This Trial?
Interventions
- DevRobust Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Icahn School of Medicine at Mount Sinai
Lead Sponsor
New York University
Collaborator
Brooklyn College of the City University of New York
Collaborator
Ohio University
Collaborator
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborator